Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...

US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi ...

ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, today announced that Seattle Children ...

Craig Hallum has recently initiated Lineage Cell Therapeutics Inc (LCTX) stock to Buy rating, as announced on August 20, 2024, according to Finviz. Earlier, on November 2, 2022, Robert W. Baird had ...

Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.0, along with a high estimate of $9.00 and a low estimate of $2.00. No alteration is ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...